# PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Source: https://onco.cc/trials/nct06961565/  
OnCo record `nct06961565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PAS-004 run by Pasithea Therapeutics Corp., now recruiting.

## Summary

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas is a phase 1 interventional study registered as NCT06961565 by Pasithea Therapeutics Corp., with 56 participants planned, started 2025-05-30. Conditions recorded: NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) and Neurofibromatosis Type 1 (NF1). Interventions recorded: PAS-004 Tablets and PAS-004 Capsule.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06961565
- Phase: 1
- Setting: A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas
- Sponsor: Pasithea Therapeutics Corp.
- Enrolled: 56

## Sources

- ClinicalTrials.gov NCT06961565: https://clinicaltrials.gov/study/NCT06961565

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PAS-004](https://onco.cc/drugs/pas-004/)
- companies: [Pasithea Therapeutics](https://onco.cc/companies/pasithea-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06961565.json